Valoctocogene roxaparvovec gene therapy demonstrates long-term efficacy in reducing bleeding episodes and factor VIII use in patients with severe hemophilia A, potentially changing the treatment landscape for this condition.

Lisocabtagene maraleucel offers a new treatment option for patients with CLL who have progressed on both BTK and BCL2 inhibitors, addressing an important unmet need in this patient population.

Nearly 70% of 340B contract pharmacies are now associated with pharmacy benefit managers, potentially shifting the program’s focus away from its original intent of supporting safety-net providers.

The loss of two oncology residents in a plane crash has left a significant void in cancer care at a major oncology center in Paraná, Brazil, highlighting the critical role of specialized medical professionals in smaller communities.

AL amyloidosis can present with distinctive periorbital signs, including petechiae and waxy eyelid papules, which may worsen with trauma.

In a phase 3 trial comparing belzutifan to everolimus for advanced renal-cell carcinoma, belzutifan demonstrated a significant improvement in progression-free survival at 18 months (24.0% vs. 8.3%, P=0.002) and objective response rate (21.9% vs. 3.5%, P<0.001).